menu
    • menu

    Company profile for 3D Medicines Corporation

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient. 3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients. 3DMed clinical laboratory is accredited by College of American Patho...
    3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient. 3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients. 3DMed clinical laboratory is accredited by College of American Pathologists (CAP) and certified by Clinical Laboratory Improvement Amendments (CLIA) to provide clinical testing in various disease areas. CAP CLIA About 3DMed. In 2018, 3DMed introduced an AI-based cancer genome.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    3D Medicines CorporationChina Flag
    Country
    Country
    China
    Address
    Address
    Block A, Building 2, No.158 Xinjunhuan Road, Pujiang Town, Minhang District, S...
    Telephone
    Telephone
    (86)021-34796586
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.3dmedcare.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug
    Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

    25 Jan 2024

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-inks-licensing-pact-with-jiangsu-alphamab-3d-medicines-for-cancer-drug/articleshow/107134381.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    25 Jan 2024
    Share Share
    SELLAS Life Sciences Announces IND Acceptance for Trial of GPS in China
    SELLAS Life Sciences Announces IND Acceptance for Trial of GPS in China

    26 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/27/2373914/0/en/SELLAS-Life-Sciences-Announces-IND-Acceptance-for-First-Clinical-Trial-of-GPS-in-China.html

    GLOBENEWSWIRE
    26 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search